RARX News and Press, Ra Pharmaceuticals Inc. From 11/07/19

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

Ra Pharmaceuticals (NASDAQ: RARX ): Q3 GAAP EPS of -$0.55 misses by $0.05 . More news on: Ra Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

First patient dosed in the global, pivotal, Phase 3 RAISE study of zilucoplan in gMG, with top-line results expected in early 2021 On track to dose first patient in the Phase 2 trial of zilucoplan in immune-mediated necrotizing myopathy (IMNM) by year-end 2019 Zilucoplan selected ...

This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position or...

Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...

This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position ...

Investment Thesis The shares of Ra Pharmaceuticals ( RARX ) more than doubled in value this month following a merger agreement with UCB SA ( UCBJF ), which valued the company at ~$2.1B. Ra’s potentially blockbuster therapy Zilucoplan is undergoing a pivotal phase 03 trial for the tr...

NEW YORK, NY / ACCESSWIRE / October 19, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Ra Pharmaceuticals, Inc . ( RARX ) related to i...

While earnings season is under way, investors in biotech stocks must also stay abreast of the latest data emerging from major medical meetings. At these events, biotech and pharmaceutical companies vie for top billing to showcase the latest results on clinical trials and new drug candidates. ...

NEW YORK / ACCESSWIRE / October 17, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Ra Pharmaceuticals, Inc . (NASDAQ: RARX ) relate...